IQVIA (NYSE:IQV) Given New $303.00 Price Target at Stifel Nicolaus

by · The Markets Daily

IQVIA (NYSE:IQV – Get Free Report) had its price target lifted by Stifel Nicolaus from $276.00 to $303.00 in a research report issued to clients and investors on Wednesday, Benzinga reports. The brokerage currently has a “buy” rating on the medical research company’s stock. Stifel Nicolaus’ target price would indicate a potential upside of 16.21% from the company’s previous close.

Other research analysts also recently issued research reports about the company. HSBC reiterated a “buy” rating and issued a $240.00 price objective on shares of IQVIA in a report on Monday, July 6th. Mizuho boosted their target price on IQVIA from $275.00 to $300.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 7th. JPMorgan Chase & Co. upped their price target on IQVIA from $225.00 to $285.00 and gave the company an “overweight” rating in a report on Wednesday, July 29th. TD Cowen increased their price target on shares of IQVIA from $233.00 to $288.00 and gave the company a “buy” rating in a research note on Wednesday, July 29th. Finally, UBS Group began coverage on shares of IQVIA in a research note on Wednesday, September 30th. They issued a “buy” rating and a $345.00 price target on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $276.00.

View Our Latest Report on IQVIA

IQVIA Stock Performance

NYSE:IQV opened at $260.74 on Wednesday. The firm has a market capitalization of $42.92 billion, a PE ratio of 23.08, a price-to-earnings-growth ratio of 2.28 and a beta of 1.17. The business’s fifty day moving average price is $258.89 and its 200 day moving average price is $211.06. The company has a debt-to-equity ratio of 2.18, a current ratio of 0.71 and a quick ratio of 0.71. IQVIA has a 12 month low of $154.50 and a 12 month high of $277.40.

IQVIA (NYSE:IQV – Get Free Report) last posted its quarterly earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share for the quarter, beating analysts’ consensus estimates of $3.03 by $0.12. The company had revenue of $4.37 billion for the quarter, compared to analysts’ expectations of $4.30 billion. IQVIA had a return on equity of 30.25% and a net margin of 8.10%. IQVIA’s quarterly revenue was up 8.7% on a year-over-year basis. During the same period last year, the firm earned $2.81 earnings per share. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. On average, sell-side analysts anticipate that IQVIA will post 11.56 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, insider Eric Sherbet sold 5,000 shares of IQVIA stock in a transaction dated Wednesday, July 29th. The stock was sold at an average price of $249.16, for a total transaction of $1,245,800.00. Following the sale, the insider owned 20,999 shares in the company, valued at approximately $5,232,110.84. The trade was a 19.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Keriann Cherofsky sold 558 shares of IQVIA stock in a transaction dated Wednesday, July 29th. The stock was sold at an average price of $245.21, for a total value of $136,827.18. Following the sale, the insider owned 2,989 shares in the company, valued at $732,932.69. This trade represents a 15.73% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 15,581 shares of company stock valued at $3,796,021 over the last ninety days. Company insiders own 1.70% of the company’s stock.

Institutional Trading of IQVIA

A number of large investors have recently made changes to their positions in the company. BlackRock Inc. acquired a new position in IQVIA during the second quarter worth approximately $2,811,292,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of IQVIA by 9.0% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,634,264 shares of the medical research company’s stock valued at $315,772,000 after acquiring an additional 134,997 shares during the period. Dimensional Fund Advisors LP grew its position in shares of IQVIA by 4.2% during the first quarter. Dimensional Fund Advisors LP now owns 1,657,696 shares of the medical research company’s stock worth $282,657,000 after acquiring an additional 66,643 shares during the last quarter. Canada Pension Plan Investment Board purchased a new position in shares of IQVIA during the second quarter worth approximately $240,911,000. Finally, Bank of America Corp DE acquired a new stake in IQVIA during the 2nd quarter worth $235,551,000. 89.62% of the stock is owned by institutional investors and hedge funds.

About IQVIA

(Get Free Report)

IQVIA Holdings Inc (NYSE: IQV) is a global provider of technology, analytics and contract research services for the life sciences industry. The company helps pharmaceutical, biotechnology and medical device organizations develop products, manage clinical trials, understand healthcare markets and improve commercial performance.

IQVIA’s offerings include clinical research and trial management, real-world data and evidence, healthcare analytics, technology platforms, consulting, and commercial services such as sales support and patient engagement.

Further Reading